MicroRNA therapeutics: towards a new era for the management of cancer and other diseases (Q39139786)

9 September 2017

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases (English)

1 reference

9 September 2017

1 reference

Rajesha Rupaimoole

1

1 reference

PubMed ID

28209991

9 September 2017

Frank J Slack

series ordinal

2

1 reference

9 September 2017

17 February 2017

1 reference

Nature Reviews Drug Discovery

9 September 2017

1 reference

9 September 2017

16

1 reference

9 September 2017

203-222

1 reference

9 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd.2016.246

9 September 2017

0 references

cites work

MicroRNAs: genomics, biogenesis, mechanism, and function

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Non-coding RNAs in human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

31 March 2020

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The let-7 family of microRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miRNA Deregulation in Cancer Cells and the Tumor Microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNAs in cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Regulation of microRNA biogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA biogenesis pathways in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

DICER1 mutations in familial pleuropulmonary blastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-34 - a microRNA replacement therapy is headed to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Therapeutic targeting of microRNAs: current status and future challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Development of microRNA therapeutics is coming of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Dicer, Drosha, and outcomes in patients with ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

c-Myc modulates microRNA processing via the transcriptional regulation of Drosha.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

A MicroRNA targeting dicer for metastasis control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

let-7 regulates Dicer expression and constitutes a negative feedback loop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The ATM kinase induces microRNA biogenesis in the DNA damage response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Transcriptional activation of miR-34a contributes to p53-mediated apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Mir-34: a new weapon against cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

PDL1 Regulation by p53 via miR-34

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

let-7 regulates self renewal and tumorigenicity of breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The let-7 microRNA represses cell proliferation pathways in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

RAS is regulated by the let-7 microRNA family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Regulatory networks defining EMT during cancer initiation and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Tumour angiogenesis regulation by the miR-200 family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Role of miR-15/16 in CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-21: a small multi-faceted RNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Inositol phosphatase SHIP1 is a primary target of miR-155

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-155 gene: a typical multifunctional microRNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-155: on the crosstalk between inflammation and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

A microRNA signature of hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA regulation of DNA repair gene expression in hypoxic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

c-Myc-regulated microRNAs modulate E2F1 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Genotype-phenotype correlations in MYCN-related Feingold syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

microRNA-10b is a prognostic biomarker for melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-221 overexpression contributes to liver tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA expression, survival, and response to interferon in liver cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MiR-15a and miR-16-1 cluster functions in human leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Human glioma growth is controlled by microRNA-10b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-221 silencing blocks hepatocellular carcinoma and promotes survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Regulation of Hepatitis C Virus Genome Replication by Xrn1 and MicroRNA-122 Binding to Individual Sites in the 5' Untranslated Region.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Hepatitis C virus RNA functionally sequesters miR-122

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

LNA-mediated microRNA silencing in non-human primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Silencing of microRNAs in vivo with 'antagomirs'

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-21 in cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-145 and miR-143 regulate smooth muscle cell fate and plasticity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

A cardiac microRNA governs systemic energy homeostasis by regulation of MED13

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA mimicry blocks pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MiR-33 contributes to the regulation of cholesterol homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

31 March 2020

The two faces of miR-29

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Treatment of HCV infection by targeting microRNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The role of the insulin-like growth factor-1 system in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNAs 103 and 107 regulate insulin sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

The duality of oncomiR addiction in the maintenance and treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA therapeutics: principles, expectations, and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Hypoxia in cancer: significance and impact on clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Predicting effective microRNA target sites in mammalian mRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Functional screening identifies miRNAs inducing cardiac regeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Biodegradable poly(lactic acid) polymers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Nanomedicine based approaches for the delivery of siRNA in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Nanocell targeting using engineered bispecific antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Nonviral delivery of synthetic siRNAs in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Dendrimer biocompatibility and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

New class of polymers for the delivery of macromolecular therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

PEG conjugated VEGF siRNA for anti-angiogenic gene therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Chitosan-based siRNA delivery systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA regulons in tumor microenvironment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Essential role of miRNAs in orchestrating the biology of the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

Inhibition of miR-15 protects against cardiac ischemic injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.246

31 March 2020

Identifiers

DOI

10.1038/NRD.2016.246

1 reference

9 September 2017

1 reference

PubMed ID

28209991